Lung cancer

Positive results from the ADAURA Phase III trial showed AstraZeneca’s Tagrisso (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared to placebo. The trial assessed osimertinib as an adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete […]

Postdoctoral and clinical fellows are invited to apply for the AACR-Lung Cancer Initiative at Johnson & Johnson Stimulating Therapeutic Advances through Research Training (START) Grant by June 21, 2023. This three-year, $225,000 grant will provide the opportunity for training and research in both academia and industry, while allowing recipients to spend one year at a […]

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Each of our top five stories this week exemplify the scientific curiosity that fuels the drug discovery sector, ultimately leading to better treatments […]

News round-up for 24-28 April by DDW Digital Content Editor Diana Spencer. Each of our top five stories this week exemplify the scientific curiosity that fuels the drug discovery sector, ultimately leading to better treatments for patients. The stories cover the efforts by research teams to discover innovative novel drugs for geographic atrophy, HIV, lung […]

Researchers at the Icahn School of Medicine at Mount Sinai have demonstrated in a preclinical study a potential new therapeutic approach to treating the most common form of lung cancer. The strategy involves inhibiting the immune-system molecule TREM2 while enhancing natural killer cells. “Our study reveals that macrophages expressing the molecule TREM2 drive the depletion […]

Patients with treatment-naïve resectable non-small cell lung cancer (NSCLC) who received neoadjuvant durvalumab (Imfinzi) plus chemotherapy and adjuvant durvalumab monotherapy had improved event-free survival (EFS) and pathological complete response (pCR) compared with those who received neoadjuvant chemotherapy alone. The results from the Phase III placebo-controlled AEGEAN clinical trial were presented at the AACR Annual Meeting […]

New data has revealed a long-term response in patients with advanced non-small cell lung cancer (NSCLC) taking Rybrevant (amivantamab). The CHRYSALIS study is evaluating amivantamab in patients with advanced non-small cell lung cancer (NSCLC) and epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease progressed on prior platinum-based chemotherapy. Data from the study […]

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  As 4 February was World Cancer Day, this week’s update focused on developments in the field of oncology. Drugs for lung cancer, lymphoma […]

News round-up for 30 January – 3 February by DDW Digital Content Editor Diana Spencer.  As February 4 is World Cancer Day, this week’s update focuses on developments in the field of oncology. Drugs for lung cancer, lymphoma and breast cancer have received regulatory approvals, an investment boost will allow the development of a novel approach to treating tumours, and […]

Following a resubmission from manufacturer Merck, the Scottish Medicines Consortium (SMC) has now approved Tepmetko (tepotinib) for use on the NHS in Scotland.   It is recommended for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition factor gene (MET) exon 14 (METex14) skipping alterations.   This change was made following […]